»ùÒòµãÍ»±äϸ°û
µãÍ»±äϸ°ûϵÊÇͨ¹ýÔÚÄ¿µÄ»ùÒòÌØ¶¨Î»µãÒýÈëµ¥¼î»ùÌæ»»»òС¹æÄ£µÄºËÜÕËá²åÈë/ȱʧ£¬£¬£¬£¬´Ó¶øÊµÏÖ׼ȷģÄâ¼²²¡Ïà¹ØÍ»±ä¡¢Ñо¿»ùÒò¹¦Ð§ºÍÂѰ×ÖʽṹµÄÖ÷Òª¹¤¾ß¡£¡£¡£¡£Ïà±ÈÓڹŰåµÄ»ùÒò±à¼·½·¨£¬£¬£¬£¬µãÍ»±äÄܹ»ÔÚ²»ÆÆËðÕûÌå»ùÒò½á¹¹µÄÇéÐÎÏÂʵÏÖ¾«×¼ÐÞÊΣ¬£¬£¬£¬Îª¿ÆÑÐÖ°Ô±Ìṩ¸üÌù½üÕæÊµÐÄÀí״̬µÄϸ°ûÄ£×Ó¡£¡£¡£¡£
ÍêÃÀÕæÈËÒÀÍÐ×ÔÖ÷ÓÅ»¯µÄ CRISPR/Cas9 Óë Prime Editing ¼¼Êõƽ̨£¬£¬£¬£¬Á¬Ïµ¸ßЧ sgRNA Éè¼ÆÓëÑÏ¿áµÄµ¥¿Ë¡ɸѡϵͳ£¬£¬£¬£¬¿ÉΪ¿Í»§¶¨ÖƶàÖÖÀàÐ͵ĵãÍ»±äϸ°ûϵ¡£¡£¡£¡£ÍêÃÀÕæÈËЧÀ;߱¸ ±à¼Ð§Âʸߴï98%¡¢ÍѰÐÂʵÍÖÁ0.1%¡¢ÑéÖ¤ÖÜÈ« µÈÌØµã£¬£¬£¬£¬Äܹ»¼ÓËÙ¿ÆÑÐÏîĿϣÍû¡£¡£¡£¡£µã»÷Éó²é100+µãÍ»±äϸ°ûÏÖ»õ¡ú
ЧÀÍÏêÇé
| ϸ°ûÀàÐÍ | ÖÖÖÖϸ°ûÀàÐÍ£¬£¬£¬£¬°üÀ¨Ö×Áö¡¢Í¨Àý¡¢¸Éϸ°û¡¢Ô´úºÍÓÀÉú»¯Ï¸°ûϵ¡£¡£¡£¡£ |
|---|---|
| ЧÀÍÀàÐÍ | Ïȵ¼±à¼Æ÷/¼î»ù±à¼Æ÷/ HDR |
| ½»¸¶±ê×¼ | »ùÒòµãÍ»±äµ¥¿Ë¡ϸ°û¡Ý1Ö꣨2¹Üϸ°û/Ö꣬£¬£¬£¬1¡Á10^6/¹Ü£© |
| ÖÜÆÚ/¼ÛÇ® |
¿ìÖÁ8ÖÜ£¬£¬£¬£¬16800ÔªÆð |
ЧÀÍÓÅÊÆ
¸ßЧµÄ±à¼ÏµÍ³
¸ßЧpegRNAÉèÅÌË㷨ϵͳ
ÔöÇ¿Ð͵ÄCas9n-RT±à¼Ã¸ÏµÍ³
¸ßЧµÄתȾϵͳ
¸ßЧµÄµ¥¿Ë¡·ÖÑ¡¼¼Êõ
רҵµÄ¼¼ÊõÖ§³ÖÍŶÓ
µãÍ»±äÒªÁì±ÈÕÕ
| ÌØÕ÷ | Ïȵ¼±à¼ | ¼î»ù±à¼Æ÷ | HDR |
|---|---|---|---|
| ÊÇ·ñÐèÒªDSB | ·ñ£¨µ¥Á´nick£© | ·ñ | ÊÇ |
| ±à¼ÀàÐÍ | µãÍ»±ä¡¢Ð¡²åÈë/ȱʧ | ½öÏÞC→T»òA→G | í§Òâ±à¼(Ð蹩Ìå) |
| ЧÂÊ | ¸ß | ¸ß | µÍ(<10%£¬£¬£¬£¬ÒÀÀµÏ¸°ûÆÆËéʹÓÃNHEJÒÖÖÆ¼ÁÈçSCR7£¬£¬£¬£¬ÌáÉýЧÂÊ) |
| ÊÊÓÃϸ°û | ÆÆËé/·ÇÆÆËéϸ°û | ÆÆËé/·ÇÆÆËéϸ°û | Ö÷񻮮Ëéϸ°û |
| ÍѰÐΣº¦ | µÍ | ÖÐ(bystander editing) | ¸ß(NHEJ½éµ¼indels) |
ЧÀÍÀàÐÍ
Ïȵ¼±à¼Æ÷
ÊÂÇéÔÀí

¼î»ù±à¼Æ÷
ÊÂÇéÔÀí

HDR
ÊÂÇéÔÀí

Àֳɰ¸Àý
ʹÓÃÏȵ¼±à¼ÔÚA549,K562,IPSCϸ°ûÖй¹½¨µ¥¼î»ùλµãÍ»±äϸ°ûϵ
| ϸ°ûÀàÐÍ | cell pool ±à¼Ð§ÂÊ | ²âÐò·åͼ | ÌôÑ¡µ¥¿Ë¡ÊýÄ¿ | µ¥¿Ë¡´¿ºÏ×ÓÊýÄ¿ |
|---|---|---|---|---|
| A549 | 98% | WT:GAGTTGCGCATTAACAGTGGTGGGA MT:GAGTTGCGCATTAACGGTGGTGGGA ![]() |
7 | 6 |
| K562 | 82% | WT:GTGGAGAAGCCCTTCGGGAGGGACC MT:GTGGAGAAGCCCCTCGGGAGGGACC ![]() |
6 | 4 |
| IPSC | 60% | WT:AGGGAACCCCAAGTTGAACTTGGCTT MT:AGGGAACCCCAAGTTCAACTTGGCTT ![]() |
8 | 2 |
ʹÓÃÏȵ¼±à¼ÔÚA549ϸ°ûÖй¹½¨Ë«Î»µãÍ»±äϸ°ûϵ
| ϸ°ûÀàÐÍ | cell pool ±à¼Ð§ÂÊ | ²âÐò·åͼ | ÌôÑ¡µ¥¿Ë¡ÊýÄ¿ | µ¥¿Ë¡´¿ºÏ×ÓÊýÄ¿ |
|---|---|---|---|---|
| A549 | 56%¼°63% | WT:CAGTCCTCAAAATCTCCATCCCTGT MT:CAGTCCTCAAAACCCCCATCCCTGT ![]() |
4 | 2 |
ʹÓÃÏȵ¼±à¼ÔÚHelaϸ°ûÖй¹½¨¼î»ù²åÈëϸ°ûϵ
| ϸ°ûÀàÐÍ | cell pool ±à¼Ð§ÂÊ | ²âÐò·åͼ | ÌôÑ¡µ¥¿Ë¡ÊýÄ¿ | µ¥¿Ë¡´¿ºÏ×ÓÊýÄ¿ |
|---|---|---|---|---|
| Hela | 64% | WT:TCCGCTACCACCAATGCCTAATGCATTTGG MT:TCCGCTACCACCAATGCTAATAACTAATGCATTTGG ![]() |
11 | 1 |
Advantage and Characteristic
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
²Î¿¼ÎÄÏ×
iPSϸ°ûÖÐʵÏÖ¶à¸ö¶þÐÍÌÇÄò²¡£¡£¡£¡£¨T2D£©Î£º¦SNVsµÄµãÍ»±ä
Ëæ×ÅÈËÀà·Ö×ÓÒÅ´«Ñ§ºÍ»ùÒò×éѧµÄÉú³¤£¬£¬£¬£¬Êýǧ¸öÓë³£¼û¼²²¡Î£º¦Ïà¹ØµÄ»ùÒòλµã±»Ê¶±ð³öÀ´£¬£¬£¬£¬ÕâЩλµãͨ³£°üÀ¨¶à¸öºòÑ¡±äÒì¡£¡£¡£¡£È»¶ø´ó´ó¶¼Óë¼²²¡Ïà¹ØµÄ±äÒìÊǷDZàÂëµÄ£¬£¬£¬£¬ÕâʹµÃʶ±ðÕâЩ±äÒì±³ºóµÄ·Ö×Ó»úÖÆ±äµÃÄÑÌâ¡£¡£¡£¡£CRISPR¼¼ÊõµÄÉú³¤Îª°ÐÏò»ùÒò×é±à¼ÌṩÁ˸ü׼ȷµÄÒªÁ죬£¬£¬£¬ÌØÊâÊÇprime editing£¬£¬£¬£¬Ëü¿ÉÒԽ鵼ÏÕЩÈκËÜÕËáÌæ»»¡£¡£¡£¡£Òò´ËÐí¶àÑо¿Ô±ÆÚÍûʹÓÃprime editingÑо¿Ìض¨»ùÒò±äÒ칦ЧÏà¹ØÐÔÖеÄÓ¦Óò¢ÔÚ¶àÐÑĿϸ°ûÖÐÌìÉúµÈ»ùÒòϵÁУ¬£¬£¬£¬ÒÔ¿ØÖÆÒÅ´«Åä¾°£¬£¬£¬£¬Í¬Ê±ÆÀ¹ÀÒò¹ûµÈλ»ùÒòµÄ¼ÁÁ¿Ð§Ó¦¡£¡£¡£¡£ ÔÚ¸ÃÎÄÕÂÖУ¬£¬£¬£¬Ñо¿Ô±ÃÇ¿ª·¢ÁËÒ»ÖÖ¸ßЧµÄCRISPR prime editing¼¼Êõ£¬£¬£¬£¬ÓÃÓÚÔÚÓÕµ¼¶àÐÑĿϸ°û£¨iPSC£©ÖÐÌìÉúЯ´øÔӺϻò´¿ºÏµÈλ»ùÒòµÄϸ°ûϵ£¬£¬£¬£¬²¢¶Ôprime editing¼¼Êõ¾ÙÐÐÓÅ»¯¡£¡£¡£¡£½Ó×ÅÑ¡ÔñÁËÓë2ÐÍÌÇÄò²¡£¡£¡£¡£¨T2D£©Î£º¦Ïà¹ØµÄÁù¸öµ¥ºËÜÕËá±äÒ죨SNVs£©¾ÙÐб༣¬£¬£¬£¬²¢Õë¶Ôÿ¸öλµã´ÓÒÅ´«Åä¾°²î±ðµÄÈËÀ๩ÌåÑÜÉúµÄiPSCsÖоÙÐб༣¬£¬£¬£¬Í¨¹ýϵÁÐʵÑéºÍ±ÈÕÕÆÀ¹À±à¼Ð§ÂÊ¡£¡£¡£¡£Ñо¿Ð§¹ûÅú×¢£¬£¬£¬£¬Ñо¿Ô±ÃÇÀÖ³ÉÌìÉúÁË27¸ö±à¼¹ýµÄiPSC¿Ë¡£¬£¬£¬£¬º¸ÇÁË6¸öÓë2ÐÍÌÇÄò²¡»òÏÈÌìÐÔ¸ßÒȵºËØÑªÖ¢£¨CHI£©Ïà¹ØµÄSNVs¡£¡£¡£¡£ËûÃÇ»¹·¢Ã÷£¬£¬£¬£¬prime editing¼¼ÊõÔÚiPSCsÖеÄЧÂʱÈÔÚHEK293Tϸ°ûÖиü¸ß¡£¡£¡£¡£×ܵÄÀ´Ëµ£¬£¬£¬£¬ÕâÏîÑо¿Õ¹Ê¾ÁËprime editing¼¼ÊõÔÚÌìÉúÌØ¶¨ÒÅ´«Åä¾°µÄiPSCsÖеÄDZÁ¦£¬£¬£¬£¬²¢ÎªÑо¿Ìض¨ÒÅ´«±äÒì¶Ô¼²²¡Ó°ÏìÌṩÁËÒ»¸öÓÐÁ¦µÄ¹¤¾ß¡£¡£¡£¡£
ͨ¹ýÀä¶³µç¾µÑо¿Prime editor¸´ºÏÌåµÄ×÷ÓÃÀú³ÌÍÆ¶¯Prime editin¼¼ÊõµÄµü´úÉý¼¶
¹ØÓÚPrime editorÔõÑùʶ±ðpegRNA²¢ÓëÄ¿µÄDNAÏ໥×÷ÓõķÖ×Ó»úÖÆÉв»ÇåÎú£¬£¬£¬£¬ÏÞÖÆÁ˶ÔPrime editingÀú³ÌµÄÃ÷È·ºÍ½øÒ»²½µÄÓÅ»¯¡£¡£¡£¡£Îª½â¾öÕâ¸öÎÊÌ⣬£¬£¬£¬Ñо¿Ö°Ô±ÔÚ¶àÖÖ״̬ϲⶨÁËPrime editorµÄÀä¶³µç¾µ(cryo-EM)½á¹¹£¬£¬£¬£¬ÎªÃ÷È·ÕâÒ»Á¢ÒìµÄ»ùÒò×鹤³ÌϵͳÌṩÁËÈ´¹¹¿ò¼Ü¡£¡£¡£¡£ Ñо¿Ö°Ô±Ê¹ÓÃÀä¶³µç¾µ¼¼Êõ£¨cryo-EM£©¶ÔPrime editor¸´ºÏÌåÔÚ²î±ð״̬ϵĽṹ¾ÙÐÐÁËÆÊÎö£¬£¬£¬£¬°üÀ¨Ô¤Æô¶¯¡¢Æô¶¯¡¢ÑÓÉìºÍÖÕֹ״̬£¬£¬£¬£¬ÀֳɻñµÃÁËPrime editor¸´ºÏÌåÔÚ¶à¸ö״̬ϵĸßÇø·ÖÂʽṹ£¬£¬£¬£¬Õ¹ÏÖÁËÆäÔÚÖ¸µ¼Äæ×ªÂ¼Àú³ÌÖеĶ¯Ì¬×ª±ä£»£»£»£»£»»ùÓڽṹÐÅÏ¢£¬£¬£¬£¬Ñо¿Ö°Ô±Éè¼ÆÁËpegRNA±äÌåºÍPrime editor±äÌ壬£¬£¬£¬²¢¶ÔM-MLV RT¾ÙÐнض̺ÍÈںϣ¬£¬£¬£¬Àֳɿª·¢ÁËÒ»ÖÖ¸üС³ß´çµÄPrime editor±äÌ壨PECO-Mini£©£¬£¬£¬£¬ËüÔÚ¼á³Ö±à¼Ð§ÂʵÄͬʱ£¬£¬£¬£¬Ìá¸ßÁËAAVÔØÌåµÄµÎ¶ÈºÍPrime editingЧÂÊ£¬£¬£¬£¬»îÐÔ²âÊÔЧ¹ûÏÔʾ¹¤³Ì»¯ºóµÄPrime editor±äÌåÔÚÌåÍâ¾ßÓÐÓëÔʼPrime editorÏ൱µÄ»îÐÔ¡£¡£¡£¡£¸ÃÑо¿Õ¹ÏÖÁËPrime editor¸´ºÏÌåÔÚ²î±ðÊÂÇé״̬ÏÂµÄ½á¹¹ÌØÕ÷£¬£¬£¬£¬ÎªÃ÷È·Æä·Ö×Ó»úÖÆÌṩÁËÖ÷ÒªÐÅÏ¢¡£¡£¡£¡£
ͨ¹ý½Ø¶ÌRTøÌá¸ß¾AAVµÝË͵ÄPrime editing±à¼Ð§ÂÊ
Prime editingÊÇÒ»ÖÖÐÂÐ͵ĻùÓÚCRISPRµÄ»ùÒò×é±à¼¼¼Êõ£¬£¬£¬£¬Ëü²»ÐèҪ˫Á´DNA¶ÏÁÑ»òÍâÔ´ÐÔ¹©ÌåÄ£°åDNA£¬£¬£¬£¬Õ¹ÏÖ³öÔÚÉúÎïҽѧÑо¿ºÍ»ùÒòÖÎÁÆ·½ÃæµÄÖØ´óDZÁ¦¡£¡£¡£¡£Ö»¹ÜPrime editing¼¼Êõ¾ßÓж๦ЧÐÔºÍ׼ȷÐÔ£¬£¬£¬£¬µ«ËüÔÚ²î±ðÀàÐ͵ı༡¢Ä¿µÄλµãºÍϸ°ûÀàÐÍÖеÄЧÂʱ£´æºÜ´ó²î±ð¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬ÎªÁËʵÏÖ¸üÆÕ±éµÄÓ¦Ó㬣¬£¬£¬ÐèÒªÌá¸ßPrime editingµÄЧÂÊ¡£¡£¡£¡£ Ñо¿Ö°Ô±É¸Ñ¡ÁË11ÖÖ²î±ðȪԴµÄRT±äÌ壬£¬£¬£¬Ê¹ÓÃGenScriptËã·¨ÓÅ»¯ÆäÈËÀàÃÜÂë×Ó£¬£¬£¬£¬·¢Ã÷PEÂѰױí´ïˮƽÌá¸ßÁË1.4±¶£»£»£»£»£»Í¨¹ýɾ³ýRNase H½á¹¹ÓòºÍ½øÒ»²½Ëõ¶ÌRTÐòÁУ¬£¬£¬£¬½¨Éè¶à¸ö½Ø¶ÌµÄPECO±äÌ壬£¬£¬£¬Ê¹Prime editorÔÚ¼á³Ö±à¼Ð§ÂʵÄͬʱ³¤¶ÈïÔÌÁË621bp£»£»£»£»£»ÎªÁËʵÏÖÓÐÓõÄË«AAVת´ïPE£¬£¬£¬£¬Ñо¿Ö°Ô±¹¹½¨ÁË»ùÓÚ²î±ðCas9ÆÆËéλµãºÍinteinµÄÆÆËéPEϵͳ£¬£¬£¬£¬È·¶¨ÁËRma 573-574ºÍ674-675ÆÆËéλµã£¬£¬£¬£¬ÕâÁ½¸öλµãÓëRma inteinÁ¬ÏµÊ¹ÓÃʱ£¬£¬£¬£¬ÏÔÖøÌá¸ßAAVÔØÌåµÄµÎ¶ÈºÍPrime editorЧÂÊ¡£¡£¡£¡£Í¨¹ý¹¤³Ì»¯Ë¢ÐºÍÓÅ»¯£¬£¬£¬£¬Ñо¿Ö°Ô±ÀÖ³ÉÌá¸ßÁËPrime editing¼¼ÊõµÄ±à¼Ð§ÂÊ£¬£¬£¬£¬²¢ÇÒ½â¾öÁËAAVÔØÌå¾ÞϸÏÞÖÆµÄÎÊÌ⣬£¬£¬£¬ÎªÎ´À´µÄ»ùÒòÖÎÁƺÍÉúÎïҽѧÑо¿ÌṩÁËÒ»¸öÔ½·¢ÓÐÓúÍÊÊÓõŤ¾ß¡£¡£¡£¡£
ͨ¹ýÑо¿Prime editin×÷ÓûúÖÆÍÆ¶¯Prime editin¼¼ÊõµÄµü´úÉý¼¶
¸ÃÎÄÕÂÆÊÎöÁËprime editing¼¼ÊõÖÐpegRNAÖ¸µ¼Äæ×ªÂ¼µÄ½á¹¹»ù´¡¡£¡£¡£¡£Ñо¿Í¨¹ý¸ßÇø·ÖÂʵĽṹÆÊÎö£¬£¬£¬£¬Õ¹ÏÖÁËPrime EditorÖеÄÒªº¦ÂѰ×ÖÊ£¬£¬£¬£¬°üÀ¨Cas9ºÍÄæ×ªÂ¼Ã¸µÄÈýά¹¹Ïó¼°ÆäÓëpegRNAµÄÏ໥×÷Óᣡ£¡£¡£ÏêϸÐÎòÁËpegRNAÔõÑùÖ¸µ¼Prime Editorʶ±ðÌØ¶¨DNAÐòÁв¢¾ÙÐÐÄæ×ªÂ¼£¬£¬£¬£¬½«Ô¤¶¨µÄ»ùÒòÐòÁвåÈëÄ¿µÄλÖᣡ£¡£¡£±ðµÄ£¬£¬£¬£¬Ñо¿»¹ÌÖÂÛÁËÒªº¦°±»ùËá²Ð»ùÔÚpegRNAÁ¬ÏµºÍÄæ×ªÂ¼Àú³ÌÖеÄ×÷Ó㬣¬£¬£¬ÆÊÎöÁËÕâЩ·Ö×Ó»¥¶¯µÄ׼ȷ»úÖÆ¡£¡£¡£¡£ÕâÒ»·¢Ã÷²»µ«ÉÁËÎÒÃǶÔPrime Editing»úÖÆµÄÃ÷È·£¬£¬£¬£¬»¹ÎªÓÅ»¯ºÍˢиü¼ÊõÌṩÁËÃû¹óµÄ½á¹¹ÐÅÏ¢£¬£¬£¬£¬Íƶ¯ÆäÔÚ»ùÒòÖÎÁƵÈÁìÓòµÄÓ¦Óᣡ£¡£¡£
ÔÚÔìѪ¸Éϸ°ûºÍ×æÏ¸°û£¨HSPCs£©ÊµÏÖHBBS»ùÒòµÄµãÍ»±ä
Á״ϸ°û²¡£¡£¡£¡£¨Sickle-cell disease, SCD£©ÊÇÒ»ÖÖÓÉβ-ÖéÂѰ׻ùÒò£¨HBB£©ÖеÄÒ»¸öA·Tµ½T·AµÄµãÍ»±äÒýÆðµÄ³£È¾É«ÌåÒþÐÔÒÅ´«²¡¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬ÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨FDA£©Åú×¼µÄΨһÖÎÓúSCDµÄÒªÁìÊÇͬÖÖÒìÌåÔìѪ¸Éϸ°ûÒÆÖ²¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬´ó´ó¶¼»¼Õßȱ·¦ÀíÏëµÄ¹©Ì壬£¬£¬£¬²¢ÇÒ¸ÃÊÖÊõ»áµ¼ÖÂÑÏÖØµÄ¶¾ÐÔ¡£¡£¡£¡£Í¨¹ýУÕý»¼Õß×ÔÉíµÄÔìѪ¸Éϸ°û£¨HSCs£©£¬£¬£¬£¬¿ÉÒÔÈÆ¹ýÃâÒß²¢·¢Ö¢£¬£¬£¬£¬²¢Ïû³ý¶Ô×éÖ¯ÏàÈÝÐÔ¹©ÌåµÄÐèÇ󡣡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬ÒÑÓÐһЩ¹ØÓÚʹÓÃCas9ºËËáøÆô¶¯µÄͬԴ¶¨ÏòÐÞ¸´£¨HDR£©ºÍÏÙÏà¹Ø²¡¶¾ÀàÐÍ6£¨AAV6£©µÝË͵ÄDNAÄ£°åÀ´Ð£ÕýSCDÍ»±äµÄÁÙ´²ÊÔÑéÑо¿ÕýÔÚ¾ÙÐÐÖС£¡£¡£¡£ ÔÚ¸ÃÎÄÕÂÖУ¬£¬£¬£¬Ñо¿Ô±ÃÇʹÓÃÓÅ»¯µÄprime editingϵͳ¶ÔSCD»¼ÕßÔìѪ¸Éϸ°ûºÍ×æÏ¸°û£¨HSPCs£©¾ÙÐÐÌåÍâУÕý£¬£¬£¬£¬Í¨¹ýµç´©¿×½«PEmax mRNAÓëºÏ³ÉµÄepegRNAºÍÇиîsgRNAÁ¬ÏµÊ¹Ó㬣¬£¬£¬Àֳɽ«SCDµÈλ»ùÒò£¨HBBS£©Ð£Õý»ØÒ°ÉúÐÍ£¨HBBA£©£¬£¬£¬£¬Ð£ÕýƵÂÊÔÚ15%µ½41%Ö®¼ä¡£¡£¡£¡£Ö®ºó£¬£¬£¬£¬Ñо¿Ô±Ãǽ«¾ÓÉÆô¶¯±à¼µÄHSPCsÒÆÖ²µ½ÃâÒßȱÏݵÄСÊóÌåÄÚ£¬£¬£¬£¬7Öܺ󣬣¬£¬£¬±à¼µÄHSPCsÔÚСÊó¹ÇËèÖÐά³ÖÁËHBBAˮƽ£¬£¬£¬£¬²¢ÏÔʾ³öÓëδ±à¼µÄ¿µ½¡¹©ÌåHSPCsÏàËÆµÄÖ²ÈëÆµÂÊ¡¢ÔìѪ·Ö½âºÍÆ×ϵ³ÉÊì¡£¡£¡£¡£ÖÎÁÆÐ§¹ûÆÀ¹À·¢Ã÷£¬£¬£¬£¬ÔÚÒÆÖ²ºóµÄСÊóÖУ¬£¬£¬£¬Æ½¾ù42%µÄÈ˺ìϸ°ûǰÌåºÍÍøÖ¯ºìϸ°û±í´ïÁËHBBA£¬£¬£¬£¬Áè¼ÝÁËÕ¹ÍûµÄÖÎÁÆÒ洦ˮƽ¡£¡£¡£¡£»£»£»£»£»ùÒòÌØÒìÐÔÆÊÎöÒ²Åú×¢Æô¶¯±à¼ÏµÍ³¾ßÓи߶ȵÄÄ¿µÄDNAÌØÒìÐÔ¡£¡£¡£¡£×îÖÕÑо¿Ð§¹û֤ʵÁ˸ü¼ÊõÊֶεÄÇå¾²ÐÔºÍЧÂÊ£¬£¬£¬£¬¾ßÓкã¾ÃЧ¹ûºÍ¶à¿Ë¡ÐÔ¡£¡£¡£¡£×ܽáÀ´Ëµ£¬£¬£¬£¬ÕâÏîÑо¿Õ¹Ê¾ÁËprime editing¼¼ÊõÔÚÖÎÁÆSCDÖеÄDZÁ¦£¬£¬£¬£¬Ö¤ÊµÎúÆäÔÚÌá¸ßÖÎÁÆÐ§¹ûºÍ½µµÍ·ÇÄ¿µÄ±à¼Î£º¦·½ÃæµÄÓÐÓÃÐÔ¡£¡£¡£¡£
¾«Ñ¡¿Í»§ÎÄÕÂ
Deep whole-genome analysis of 494 hepatocellular carcinomas
È«ÇòÁè¼ÝÒ»°ëµÄ¸Îϸ°û°©£¨HCC£©²¡Àý±¬·¢ÔÚÖйú£¬£¬£¬£¬µ«ÏÖÔÚÕë¶ÔÖйúÈËȺÖÐÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©Ïà¹ØHCCµÄÈ«»ùÒò×éÆÊÎöÑо¿ºÜÊÇÓÐÏÞ¡£¡£¡£¡£ÎªÁËÍ»ÆÆÕâÖÖÏÞÖÆ£¬£¬£¬£¬Ñо¿Ö°Ô±Æô¶¯ÁË“Öйú¸Î°©Í¼Æ×ÏîÄ¿”£¨CLCA£©£¬£¬£¬£¬Ö¼ÔÚ¶ÔÖйúÈËȺÖеÄHCC¾ÙÐдó¹æÄ£µÄÈ«»ùÒò×éÆÊÎöÒÔÃ÷È·ÆäÆæÒìµÄ·¢²¡»úÖÆºÍ½ø»¯Àú³Ì¡£¡£¡£¡£¸ÃÏîÄ¿¶Ô494ÀýHCCÖ×ÁöÑù±¾¾ÙÐÐÁËÉî¶ÈÈ«»ùÒò×é²âÐò£¨Æ½¾ù²âÐòÉî¶ÈΪ120×£©£¬£¬£¬£¬²¢ÆÊÎöÁËÆ¥ÅäµÄ±ÈÕÕѪҺÑù±¾£¬£¬£¬£¬Õ¹ÏÖÁËHBVÏà¹ØHCCµÄÏêϸ»ùÒò×éÌØÕ÷¡£¡£¡£¡£Ñо¿·¢Ã÷£¬£¬£¬£¬³ýÁËÒÑÖªµÄ±àÂëÇøÇý¶¯»ùÒò£¨ÈçTP53ºÍCTNNB1£©Í⣬£¬£¬£¬»¹±£´æ6¸öеıàÂëÇøÇý¶¯»ùÒò£¨°üÀ¨FGA£©ºÍ31¸ö·Ç±àÂëÇøÇý¶¯»ùÒò¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬Ñо¿»¹Õ¹ÏÖ5ÖÖеÄÍ»±äÌØÕ÷£¨°üÀ¨SBS_H8£©£¬£¬£¬£¬ÒÔ¼°HBVÕûºÏÐγÉϸ°ûÍâ»·×´DNA£¨ecDNA£©µÄÕ÷Ï󣬣¬£¬£¬ÕâЩecDNA¿Éµ¼Ö°©»ùÒòÀ©ÔöºÍ±í´ïÔöÌí¡£¡£¡£¡£Í¨¹ý¹¦Ð§Ñé֤ʵÑ飬£¬£¬£¬Ñо¿Ö°Ô±Ö¤ÊµÁËFGA¡¢PPP1R12BºÍKCNJ12µÈ»ùÒòµÄÍ»±äÄܹ»ÏÔÖøÓ°ÏìHCCϸ°ûµÄÔöÖ³¡¢Ç¨áãºÍÇÖÏ®ÄÜÁ¦¡£¡£¡£¡£ÕâÏîÑо¿Ð§¹û²»µ«¸»ºñÁËÈËÃǶÔHCC»ùÒò×éѧµÄÃ÷È·£¬£¬£¬£¬Ò²ÎªHCCµÄÕï¶ÏºÍÖÎÁÆÌṩÁËеÄDZÔڰе㡣¡£¡£¡£

ºòÑ¡Çý¶¯Òò×Ӹſö
Targeted Macrophage CRISPR-Cas13 mRNA Editing in Immunotherapy for Tendon Injury
¼¡ëìËðÉ˼±ÐÔÑ×Ö¢ÆÚÖУ¬£¬£¬£¬¾ÞÊÉϸ°ûÌ«¹ý¼¤»î»áµ¼Ö±àÂë¹ÇÇÅÂѰ×OPNµÄSPP1¹ý±í´ï£¬£¬£¬£¬Ó°Ïì×éÖ¯ÔÙÉú¡£¡£¡£¡£CRISPR-Cas13ÓÉÓÚ¾ßÓÐRNA±à¼ºÍ¿ìËÙ½µ½âµÄÄÜÁ¦£¬£¬£¬£¬ÔÚ×éÖ¯ÐÞ¸´·½Ãæ¾ßÓÐÖØ´óDZÁ¦£¬£¬£¬£¬µ«È±·¦ºÏÊÊÓÐÓõĵÝËÍÒªÁì¡£¡£¡£¡£¶Ô´Ë£¬£¬£¬£¬Ñо¿Ö°Ô±ÏµÍ³É¸Ñ¡ÁËÕë¶Ô¾ÞÊÉϸ°ûµÄÑôÀë×Ó¾ÛºÏÎ£¬£¬£¬¿ª·¢ÁËÒ»ÖÖÄܹ»¸ßЧµÝËÍCas13ºËÌǺËÂѰ׸´ºÏÎCas13 RNP£©½øÈë¾ÞÊÉϸ°ûµÄÄÉÃ×´ØÔØÌå¡£¡£¡£¡£Í¨¹ý·´Ó¦ÐÔÑõÖÖ£¨ROS£©ÏìÓ¦ÐÔÊÍ·Å»úÖÆ£¬£¬£¬£¬¸ÃϵͳÄܹ»ÔÚ¼¡ëìËðÉ˵ļ±ÐÔÑ×֢΢ÇéÐÎÖÐÌØÒìÐÔÒÖÖÆ¾ÞÊÉϸ°ûÖÐSPP1µÄ¹ý±í´ï¡£¡£¡£¡£ÊµÑéЧ¹ûÅú×¢£¬£¬£¬£¬ÕâÖÖ°ÐÏò²ßÂÔÏÔÖøïÔÌÁËËðÉËÓÕµ¼µÄSPP1±¬·¢¾ÞÊÉϸ°ûµÄ·ºÆð£¬£¬£¬£¬½µµÍÁ˳ÉÏËάϸ°ûµÄ¼¤»î£¬£¬£¬£¬²¢¼õÇáÁ˼¡ëìÖÜΧµÄÕ³Á¬Ðγɡ£¡£¡£¡£±ðµÄ£¬£¬£¬£¬¸ÃÑо¿»¹Õ¹ÏÖÁËSPP1ͨ¹ýCD44/AKTÐźÅͨ·Ôö½ø³ÉÏËάϸ°û»î»¯ºÍǨáãµÄ»úÖÆ£¬£¬£¬£¬²¢Í¨¹ýÒÖÖÆÕâһͨ·ÓÐÓûº½âÁ˼¡ëìËðÉ˺óµÄÕ³Á¬ÎÊÌâ¡£¡£¡£¡£

ÓÃÓÚPAÖÎÁƵľÞÊÉϸ°ûÃâÒß΢ÇéÐ줻îmRNA±à¼²ßÂÔµÄʾÒâͼ
Electrical stimulation of piezoelectric BaTiO3 coated Ti6Al4V scaffolds promotes anti-inflammatory polarization of macrophage and bone repair via MAPK/JNK inhibition and OXPHOS activation
¼¹ËèËðÉË£¨SCI£©ÊÇÒ»ÖÖµ¼Ö¸ÐÊÜ×ÔÖ÷Éñ¾ºÍÔ˶¯¹¦Ð§µÄÓÀÊÀÐÔË𺦵ÄÑÏÖØÖ²ÐÐÔ¼²²¡¡£¡£¡£¡£¸Éϸ°ûÁÆ·¨£¬£¬£¬£¬ÓÈÆäÊǼä³äÖʸÉϸ°û£¨MSCs£©£¬£¬£¬£¬ÔÚSCIÖÎÁÆÖÐÕ¹ÏÖ³öÖØ´óDZÁ¦µ«ÆäÔÙÉúÄÜÁ¦ÓÐÏÞ£¬£¬£¬£¬ÕâÏÞÖÆÁËÆäÔÚ×éÖ¯ÔÙÉúÖеÄÓ¦Óᣡ£¡£¡£Ñо¿ÍŶÓÊӲ쵽ABPCsÑÜÉúµÄEVs£¨EVsABPC£©¿ÉÄÜЯ´øÔö½ø×éÖ¯ÔÙÉúµÄÉúÎï»îÐÔÐźţ¬£¬£¬£¬Òò´ËËûÃÇ´Ó¹½ÇÑ¿»ù×æÏ¸°û£¨ABPCs£©ÖÐÌáÈ¡²¢ÐÞÊÎÁËϸ°ûÍâÄÒÅÝ£¨EVsABPC£©£¬£¬£¬£¬²¢½«ÆäÓ¦ÓÃÓÚ¼¹ËèËðÉË£¨SCI£©µÄÖÎÁÆÑо¿¡£¡£¡£¡£Ñо¿Ö°Ô±·¢Ã÷EVsABPCÄܹ»ÏÔÖøÔöÇ¿Éñ¾¸Éϸ°û£¨NSCs£©µÄÔöÖ³£¬£¬£¬£¬Ôö½øÖáÍ»Éú³¤£¬£¬£¬£¬ïÔÌÉñ¾ÔªµòÍö£¬£¬£¬£¬²¢Í¨¹ýµ÷ÀíÑ×Ö¢·´Ó¦½«¾ÞÊÉϸ°û´Ó´ÙÑ×µÄM1Ðͼ«»¯Îª¿¹Ñ×µÄM2ÐÍ¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬¾Óɹ¤³Ì»¯Ë¢ÐµÄEVsABPC£¨Í¨¹ý¼¤»îϸ°û´©Í¸ëÄÐÞÊΣ©Äܹ»¸üÓÐÓõذÐÏòSCIËðÉ˲¿Î»£¬£¬£¬£¬ÏÔÖø¸ÄÉÆÉñ¾ÔÙÉúºÍÔ˶¯¹¦Ð§»Ö¸´¡£¡£¡£¡£ÕâЩЧ¹ûÅú×¢£¬£¬£¬£¬EVsABPCÊÇÒ»ÖÖ¼«¾ßDZÁ¦µÄSCIÖÎÁƺòÑ¡¼Æ»®¡£¡£¡£¡£

ͼ½âÕªÒª
Generation of recombinant antibodies by mammalian expression system for detecting S-metolachlor in environmental waters
S-Òì±û¼×²Ý°·£¨S-MET£©ÊÇÎÒ¹úÉú²úºÍʹÓÃÁ¿×î´óµÄ³ý²Ý¼ÁÖ®Ò»£¬£¬£¬£¬Æä»¯Ñ§ÌØÕ÷µ¼ÖÂÆä¿ÉÔÚÍÁÈÀÖг¤ÆÚ±£´æÒÔ¼°ÈÝÒ×ͨ¹ýÁÜÈܺͳÁ½µÎÛȾµØ±íË®ºÍµØÏÂË®£¬£¬£¬£¬×îÖÕÓ°ÏìÖ²ÎïÉú³¤ºÍͨ¹ýʳÎïÁ´Î£º¦ÈËÀàÉúÃü¿µ½¡¡£¡£¡£¡£¼øÓÚÏÖÓмì²âÒªÁìµÄ¾ÖÏÞÐԺͶԸßЧÆÊÎö¼¼ÊõµÄÆÈÇÐÐèÇ󣬣¬£¬£¬¸ÃÑо¿ÒÔS-metolachlorΪ¹¤¾ß£¬£¬£¬£¬Ê¹Óò¸È鶯Îï±í´ïϵͳÌìÉúÏà¹ØÖØ×鿹Ìå¡£¡£¡£¡£ÔÚÀֳɱí´ï¿¹ÌåµÄ»ù´¡ÉÏ£¬£¬£¬£¬Àֳɽ¨ÉèÁË»ùÓÚÕâЩ¿¹ÌåµÄÃâÒ߯ÊÎöÒªÁ죬£¬£¬£¬ÓÃÓÚ¼à²âÇéÐÎË®ÑùÖеÄS-Òì±û¼×²Ý°·²ÐÁô¡£¡£¡£¡£icELISAЧ¹ûÏÔʾ£¬£¬£¬£¬ÖØ×鿹ÌåµÄѸËٶȺÍÌØÒìÐÔÓëÇ×±¾µ¥¿¹ÏàËÆ£¬£¬£¬£¬¿É¼á³ÖÔÓеÄÉúÎïѧ»îÐÔ£¬£¬£¬£¬¹ØÓڽˮ¡¢Å©ÌïË®ºÍ×ÔÀ´Ë®ÖеÄS-MET£¬£¬£¬£¬¾ßÓÐÓÅÒìµÄ׼ȷÐÔºÍÖØ¸´ÐÔ¡£¡£¡£¡£

ͼ½âÕªÒª
Dumbbell probe initiated multi-rolling circle amplification assisted CRISPR/Cas12a for highly sensitive detection of clinical microRNA
ϸСRNA£¨miRNA£©ÊÇÒ»ÀàСµÄ·Ç±àÂëRNA·Ö×Ó£¬£¬£¬£¬Í¨¹ýÓëÌØ¶¨°Ð»ùÒòµÄÐÅʹRNA£¨mRNA£©Ï໥×÷ÓÃÀ´µ÷¿Ø»ùÒò±í´ï¡£¡£¡£¡£miRNAÔÚ¶àÖÖ¼²²¡µÄ±¬·¢¡¢Éú³¤Àú³ÌÖÐÊÎÑÝ×ÅÖ÷Òª½ÇÉ«£¬£¬£¬£¬±»ÒÔΪÊǼ«¾ßDZÁ¦µÄ¼²²¡ÉúÎï±ê¼ÇÎï¡£¡£¡£¡£¸ÃÑо¿Ê¹ÓÃCRISPR/Cas12a¿ª·¢ÁËÒ»ÖÖΪDBmRCAµÄÐÂÐÍmiRNA¼ì²â¼¼Êõ¡£¡£¡£¡£¸Ã¼¼ÊõʹÓÃÎÞÅþÁ¬Ã¸µÄÑÆÁå̽ÕëºÍ¸ßѸËٶȵÄCRISPR/Cas12aÐźÅÊä³ö²ßÂÔ£¬£¬£¬£¬ÊµÏÖÁËÔÚ30·ÖÖÓÄÚ¶ÔmiRNAµÄ¸ß¾«¶È¶¨Á¿ÆÊÎö¡£¡£¡£¡£Ñо¿ÍŶÓͨ¹ýÁÙ´²Ñù±¾ÑéÖ¤Á˸ü¼ÊõµÄÓÐÓÃÐÔ£¬£¬£¬£¬·¢Ã÷miR-200aºÍmiR-126Ôڷΰ©×éÖ¯Öеıí´ïˮƽÏÔÖø½µµÍ£¬£¬£¬£¬ÇҸü¼ÊõÓë¹Å°åÒªÁìЧ¹ûÒ»Ö¡£¡£¡£¡£DBmRCA¼¼Êõ¾ßÓÐʱ¼äЧÂʸߡ¢Ñ¸ËÙ¶ÈÇ¿ºÍ²Ù×÷Á÷³Ì¼ò»¯µÈÓŵ㣬£¬£¬£¬ÎªÁÙ´²miRNAÆÊÎöÌṩÁËÒ»ÖÖ¿É¿¿µÄ¹¤¾ß£¬£¬£¬£¬ÓÐÍûÖúÁ¦·Î°©µÄÔçÆÚÕï¶ÏºÍÖÎÁÆ¡£¡£¡£¡£

ͼ½âÕªÒª
ÍêÃÀÕæÈË




